Non-small Cell Lung Cancer Stage III Clinical Trial
Official title:
A Prospective, Open-labelled, Randomized, Multicenter Phase II Study to Evaluate Efficacy and Safety of Erlotinib vs NP Chemotherapy as Adjuvant Therapy in Post Radical Operation NSCLC Patients With EGFR19 or 21 Exon Mutation
This study is to compare 2-year Disease Free Survival Rate (DFSR) in post radical operation IIIA Non-Small Cell Lung Cancer (NSCLC) patients with Epidermal Growth Factor Receptor (EGFR) 19 or 21 exon mutation treated Erlotinib vs NP chemotherapy as adjuvant therapy.
Status | Active, not recruiting |
Enrollment | 94 |
Est. completion date | October 2020 |
Est. primary completion date | October 2020 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years to 75 Years |
Eligibility |
Inclusion Criteria: - IIIA NSCLC patients according to TMN-staging of Lung Staging Standard version 7 2009, confirmed by histopathology or cytology after radical operation, and having EGFR exon 19 deletion mutation or exon 21 L858R single base substitution; - Accept study adjuvant therapy within 6 weeks post radical operation; - ECOP PS 0-1; Life expectancy =12 weeks; - Hematology: absolute neutrophil count (ANC) =1.5×10^9/L; platelet count =100×10^9/L; hemoglobin concentration = 9.0 g/dL (permit to maintain hematologic criteria by blood transfusion); - Liver Function: TBil =1.5xULN; ALT and AST =2.5xULN; - Renal Function: Cr =1.25xULN, and Ccr =60ml/min; - Female patients of childbearing potential must have a negative serum or urine pregnancy test within 7 days before study treatment; - Signed inform consent form by patient or his/her legal representative; - Comply with study protocol and procedure, and be able to take oral medication; Aged =18 years and ?75 years; - Eligible patients of reproductive potential (both sexes) must agree to use a reliable method of birth control before enrollment, during the study period and for at least 30 days after their last dose of study therapy; Exclusion Criteria: - Having treated by Her-Target therapy, i.e. erlotinib, gefitinib, cetuximab, trastuzumab; - Having treated by any systemic anti-tumor therapy of NSCLC, including cytotoxic therapy, target medication treatment (i.e. monoclonal antibody), investigational therapy; - Having local radiotherapy of NSCLC; Upper gastrointestinal physiological disorders, or malabsorption syndrome, or intolerance of oral medication, or active peptic ulcer; - The findings in radical operation are lymph nodes with extracapsular invasion, or fusion, or all of dissection lymph nodes positive by pathology; - Diagnosed other malignant tumor besides NSCLC within 5 years prior the study treatment (except having simple surgical resection with 5-year disease free survival,cured in situ of cervical carcinoma, cured basal cell carcinoma and bladder epithelial tumor); - Confirmed recurrent cancer by Clinical objective evidence (pathology or radiography images) before the study adjuvant therapy; - Known hypersensitivity to platinum, Vinorelbine, EGFR-TKI agents or relevant components in the formulation; - Uncontrolled eye inflammation or infection, or any potential circumstances lead to eye inflammation or infection; - Active interstitial lung disease (ILD) by any clinical evidence; patients with any co-morbidities, or motalic disorders, or any abnormal findings in physical examination or laboratory tests are suspected to have contraindication of study therapy or high risk of study treatment complications; - Any unstable systemic disease, including active infection, uncontrolled hypertension, unstable angina, angina starting in latest 3 months, Congestive heart failure (NYHA = II), myocardial infarction within 6 months prior enrollment, under medication treatment of severe arrhythmia, liver, renal or metabolic disease; - know HIV infection Pregnant or breastfeeding women; - ECOG PS =2; - Mixed with small cell lung cancer; - Other conditions investigators evaluate that patient is not eligible to this study. |
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
China | Beijing Cancer Hospital | Beijing | |
China | Chinese PLA General Hospital | Beijing | |
China | The second people's hospital of Sichuan | Chengdu | |
China | Fujian Medical University Union Hospital | Fuzhou | |
China | Sun Yat-Sen University Cancer Center | Guangzhou | |
China | Zhejiang Cancer Hospital | Hangzhou | |
China | The third affiliated hospital of Harbin Medical Univer | Harbin | |
China | The affiliated hospital of medical college Qingdao University | Qingdao | |
China | Fudan University Shanghai Cancer Center | Shanghai | |
China | Zhongshan Hospital Fudan University | Shanghai | |
China | Liaoning Cancer Hospital & Institute | Shenyang | |
China | Hebei Provincial Tumor Hospital | Shijiazhuang | |
China | The first affiliated hospital of Soochow University | Suzhou | |
China | Tianjin Medical University Cancer Institute and Hospital | Tianjin | Tianjin |
China | The fourth military medical university,Tangdu Hospital | Xi'an |
Lead Sponsor | Collaborator |
---|---|
Tianjin Medical University Cancer Institute and Hospital | Roche Pharma AG |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | 2-year disease free survival rate (DFSR) | 2-year disease free survival rate is defined as the estimation percentage of disease free survival patients with study treatment at 2-year. | 2 years | No |
Secondary | disease free survival | Disease free survival is defined as the time from randomization to disease recurrence or death which comes first. | 5 years | No |
Secondary | overall survival (OS) | Overall survival is defined as the time from randomization to death. | 5 years | No |
Secondary | Quality of Life | The score of Functional Assessment of Cancer Therapy - Lung (FACT-L) subscale and Lung Cancer Symptom Scale (LCSS) | 5 years | No |
Secondary | Adverse Event (AE) | frequency of Adverse Event | 5 years | Yes |
Secondary | Serious Adverse Event (SAE) | Frequency of Serious Adverse Event (SAE) | 5 years | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05557552 -
Sequential Chemo-immunotherapy Plus Thoracic Radiotherapy for Elderly and/or Frail Stage III Non-small-cell Lung Cancer
|
N/A | |
Active, not recruiting |
NCT04765709 -
Durvalumab and Chemotherapy Induction Followed by Durvalumab and Radiotherapy in Large Volume Stage III NSCLC
|
Phase 2 | |
Not yet recruiting |
NCT06031597 -
Radiotherapy Combined With ICIs as Treatment for LA-NSCLC After Failing Induction Immunochemotherapy
|
Phase 3 | |
Recruiting |
NCT04728724 -
Neoadjuvant Immunotherapy for Stage III Non-small Cell Lung Cancer
|
Phase 2 | |
Not yet recruiting |
NCT05451173 -
Combining ICI With SBRT or HypoFrx-RT for ES NSCLC
|
Phase 1/Phase 2 | |
Completed |
NCT06015815 -
The Association of MicroRNA21-155 Levels With Acute Side Effects In Patients With Stage III NSCLC With Definitive CRT
|
||
Completed |
NCT03728556 -
A Study of CS1001 in Subjects With Stage III Non-Small Cell Lung Cancer
|
Phase 3 | |
Recruiting |
NCT04586465 -
Dynamic PET/CT Evaluated the Response of Neoadjuvant Anti-PD1 Combination With Chemotherapy for Ⅱa-Ⅲb NSCLC
|
Phase 2 | |
Not yet recruiting |
NCT05548504 -
Heterogeneously Hypofractionated Radiotherapy for Locally Advanced NSCLC
|
Phase 2 | |
Completed |
NCT02434081 -
NIvolumab COmbination With Standard First-line Chemotherapy and Radiotherapy in Locally Advanced Stage IIIA/B Non-Small Cell Lung Carcinoma
|
Phase 2 | |
Not yet recruiting |
NCT02946216 -
ALK/ROS1/MET Mutations on Plasma ctDNA in Patients With NSCLC
|
N/A | |
Completed |
NCT03550482 -
Oncoxin® and Quality of Life in Cancer Patients
|
Phase 4 | |
Recruiting |
NCT05398094 -
Clinical Trial of AMG510 in Stage III Unresectable NSCLC KRAS p.G12C Patients and Ineligible for Chemo-radiotherapy
|
Phase 2 | |
Completed |
NCT02418234 -
T790M Mutation on ctDNA in Patients With NSCLC After EGFR-TKI Failure
|
N/A | |
Recruiting |
NCT05338619 -
A Study of Lazertinib as Consolidation Therapy in Patients With Locally Advanced, Unresectable, EGFR-Mutant Non-Small Cell Lung Cancer (Stage III) Following Chemoradiation Therapy
|
Phase 2 | |
Not yet recruiting |
NCT05414630 -
A Study of Envafolimab in Subjects With Stage III Non-Small Cell Lung Cancer
|
Phase 2 | |
Withdrawn |
NCT04941365 -
Quantifying Systemic Immunosuppression to Personalize Cancer Therapy
|
N/A | |
Active, not recruiting |
NCT04699721 -
Clinical Study of Neoadjuvant Chemotherapy and Immunotherapy Combined With Probiotics in Patients With Potential/Resectable NSCLC
|
Phase 1 | |
Recruiting |
NCT04878952 -
Testing the Addition of Activity Monitoring With a Wearable Electronic Device to Improve Patient Care During Treatment for Lung Cancer
|
N/A | |
Recruiting |
NCT04716946 -
Treating Early-stage Non-Small Cell Lung Cancer With Durvalumab and Radiation Therapy
|
Phase 2 |